The conversation addressed the various ways that the challenges that the COVID-19 pandemic created for clinical trials in 2020 played out in the drug development presentations at #ILC2021: a higher level of retrospective analysis of earlier trials and relatively few pieces of novel Phase 2b or Phase 3 research adding to knowledge and insight. The group noted that cirrhosis received relatively more attention and even some fresh data as with the efruxifermin late-breaker publication. Finally, the group discussed some of the studies and insights we can expect to see between now and 2022.
TOPICS: 89bio, Akero Therapeutics, aldafermin, Bristol-Myers Squibb, cilafexor, cirrhosis, COVID-19, Diabetes, Diagnostic Tests, DrugTrial, efruxifermin, Fibrosis Level 3, Fibrosis Level 4, lanifibranor, Madrigal, NGM Biopharmaceuticals, Novo Nordisk, Phase3, Semaglutide, Resmetirom, ILC2021
Surfing The NASH Tsunami is brought to you by HEP Dynamics
#HEPdynamics #SurfingNASH #podcast